Written by the Nuvirox Research Team
Key points
- A randomized, placebo-controlled trial found that nicotinamide riboside cut a key airway inflammation marker (sputum IL-8) by over 50% in COPD patients.
- The effect persisted 12 weeks after stopping treatment, and NAD+ levels were lower in COPD patients than in lung-healthy controls to begin with.
- This is a real, well-designed human trial — but it measured an inflammation marker over 6 weeks, not lung function, exacerbations, or long-term outcomes.
Short answer: yes, and this is genuinely one of the stronger human trials in NAD+ research — but it's important to be precise about what it actually measured.
Why would NAD+ matter for COPD?
COPD has been described by researchers as a disease of accelerated lung aging, driven by chronic smoking-related DNA damage and inflammation. Since NAD+ is central to both DNA repair and to regulating age-related inflammation and cellular senescence, and since NAD+ is known to decline with aging generally, researchers hypothesized that COPD patients might have depleted lung NAD+ contributing to their disease, and that restoring it might calm the underlying airway inflammation.
What does the evidence actually show?
A randomized, double-blind, placebo-controlled trial (published in Nature Aging, 2024) treated 40 patients with stable COPD with nicotinamide riboside for 6 weeks, followed by a 12-week observation period. The researchers first confirmed that NAD+ levels were lower in COPD patients compared with lung-healthy controls and correlated with lung function. The primary outcome was change in sputum interleukin-8 (IL-8), a key marker of airway inflammation. NR treatment produced a 52.6% reduction in IL-8 compared to placebo at 6 weeks (95% CI: -75.7% to -7.6%; p=0.030) — and remarkably, this effect persisted at the 12-week follow-up, well after treatment had stopped (-63.7%; p=0.034).
Study snapshot: NR-COPD randomized trial (Norheim et al., Nature Aging 2024)
| Design | Randomized, double-blind, placebo-controlled |
| N | 40 patients with stable COPD |
| Duration | 6 weeks treatment + 12-week follow-up |
| Primary outcome | Change in sputum IL-8 (airway inflammation marker) |
| Finding | -52.6% IL-8 at 6 weeks (p=0.030); effect persisted at 12-week follow-up |
The honest counterweight
This trial measured a biomarker — sputum IL-8 — not lung function tests (like FEV1/spirometry), exacerbation rates, hospitalizations, symptom scores, or mortality. A drop in an inflammation marker is a genuinely encouraging signal and a reasonable basis for larger follow-up studies, but it is not the same claim as "NR improves breathing" or "NR reduces COPD flare-ups." The trial was also relatively small (40 patients) and short (6 weeks of active treatment). A subsequent analysis suggested the effect may be more relevant in patients with noneosinophilic COPD and a smoking history specifically, which is a useful detail but also a reminder that COPD is not one uniform disease.
When to see a doctor
COPD is a progressive, incurable, and potentially serious lung disease, and management (including inhaled medications, pulmonary rehabilitation, oxygen therapy where needed, and smoking cessation) should be directed by a pulmonologist or primary care physician. No supplement, however promising the early data, is a substitute for guideline-based COPD care.
What's actually proven to help COPD
Smoking cessation remains the single most impactful intervention for slowing COPD progression. Inhaled bronchodilators and corticosteroids (as appropriate for disease severity), pulmonary rehabilitation programs, vaccination against respiratory infections, and supplemental oxygen for appropriate patients all have strong evidence behind them.
How does this fit with other NAD+ and inflammation research?
The IL-8 reduction seen in the COPD trial fits within the broader pattern documented in our coverage of NAD+ and inflammation, where NAD+-dependent sirtuin activity is repeatedly linked to calming excessive inflammatory signaling across multiple organ systems. It's also worth situating this alongside vascular research: a separate randomized trial in peripheral artery disease patients (the NICE trial) found NR meaningfully improved 6-minute walk distance, a functional outcome more directly comparable to the kind of real-world benefit COPD patients care about, discussed further in our page on NAD+ and circulation.
One additional detail worth knowing: the COPD trial specifically found the anti-inflammatory effect may be more pronounced in patients with noneosinophilic COPD (a specific inflammatory subtype identified by blood eosinophil counts) and a smoking history, rather than uniformly across all COPD patients. This kind of subtype-specific finding is common in modern respiratory research and is part of why "the trial showed a benefit" doesn't automatically mean "this will work the same way for every person with COPD" — it's a nuance worth discussing with your pulmonologist if you're curious how it might apply to your specific case.
Context on the broader research landscape: this COPD trial stands out because it's one of relatively few NAD+ precursor trials with a clearly significant primary outcome and persistent effect at follow-up, which is why it's frequently cited as one of the more compelling human data points in the entire NAD+ precursor research field, not just within respiratory disease research specifically.
If you have COPD and are curious whether you might be a candidate for related ongoing or future trials, ask your pulmonologist directly; academic medical centers running respiratory NAD+ research (including the Danish team behind this trial) sometimes have expanded studies recruiting, which is a meaningfully different path than simply adding an over-the-counter supplement to your existing regimen without medical guidance.
It's worth keeping in mind that this single trial, while well-designed, is also the first of its kind for this specific combination and outcome, and replication in additional independent research groups would meaningfully strengthen confidence in the finding, which is the normal and expected next step for any single positive clinical trial regardless of the disease area.
If you have COPD, this trial is genuinely worth discussing with your pulmonologist, both because it's a real and rigorous finding and because your doctor can help you weigh it against your specific disease subtype and current treatment plan.
Frequently asked questions
Does NAD+ actually help COPD?
A randomized trial found it significantly reduced an airway inflammation marker, which is a genuinely positive and unusual result — but it didn't measure lung function or symptom outcomes directly.
Should I take an NAD+ supplement instead of my COPD medications?
No. This trial doesn't support replacing any part of standard COPD management, and stopping prescribed treatments without medical guidance can be dangerous.
Is this the same NAD+ precursor as in over-the-counter supplements?
The trial used nicotinamide riboside, which is available as an over-the-counter supplement, but the trial dose, formulation, and monitoring were clinically controlled — discuss with your doctor before adding any supplement to a COPD treatment plan.
From Nuvirox
Why we formulated NAD+ Restore
To be direct: NAD+ Restore is a general wellness supplement, not a treatment for this condition, and it shouldn't be used as a substitute for medical care. If you're separately interested in cellular energy support once your care team is in the loop, here's what's in it.
- 500 mg Nicotinamide Riboside Chloride (NR) — one of the two most-researched NAD+ precursors, within the dose range used in published human trials
- 150 mg trans-resveratrol (Japanese Knotweed) + 50 mg quercetin (Sophora japonica) — polyphenols studied alongside NAD+ pathways for cellular health support
- 10 mg galactomannans from fenugreek — to support absorption
- 60-day money-back guarantee — long enough to actually evaluate it the way the research says you should
The bottom line: this is one of the more rigorous, positive human trials in the NAD+ precursor research world — a real reduction in a meaningful inflammation marker, with a persistent effect. It's a genuinely encouraging data point for future research, not yet a replacement for standard COPD care.
References
- Norheim KL, et al. Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial. Nat Aging. 2024. PMID: 39548320.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not a substitute for professional medical advice.